Jean-Michel BOULER

Jean-Michel Bouler (56 years old) was appointed as full-Professor in the Department of Materials Science (Dental College - University of Nantes) in September 2005 after serving as Assistant-Professor since 1999. Prof. Bouler completed a BSc and a MSc in chemistry respectively at University of Nantes, France and University of Wales, U.K. before joining a Biomaterials Research Center at INSERM to study for a PhD in bioceramics.

Prof. Bouler was then asked to run the BIOMAT Group within an INSERM Unit focused in Bone & Dental Tissue Engineering from 1999 till 2014. Then he joined a large CNRS research unit (CEISAM UMR 6230, https://ceisam.univ-nantes.fr) where he develops hybrid CaP biomaterials able to release specific therapeutic agents. Areas of particular interest in the Group include the synthesis and characterisation of novel drug-combined calcium phosphate matrices with the objective of systematically studying the biological effects of the association of various drugs and/or ions with calcium phosphate biomaterials. Research in this field was funded through numerous ANR Programs involving academic laboratories, clinical centers and private companies. These collaborations have led to 9 patents and patent applications and some specific systems are now being taken forward to clinical applications and CE/FDA markings.

Since january 2017, Prof Bouler was appointed Director of CEISAM Research Institute.

Jean-Michel Bouler has been consulting for orthopaedics major companies for more than 15 years and has co-funded three biotech companies (Biomatlante in 1995, Graftys in 2005 and Biomadvanced Diagnostics in 2021).

Jean-Michel Bouler has been involved in several scientific panels evaluating biomaterials programs for Agence Nationale pour la Recherche' (ANR, France), Fundação para a Ciência e a Tecnologia' (FCT, Portugal) and for 6th / 7th European Frame Programs.

Scientific record (Scopus, Nov 2022)

more than 140 original or review articles in international peer-reviewed journals

Sum of the times cited without self-citations : > 7 000

h Index = 50

9 patent clusters

5 Selected publications:

C. Mellier, F. Fayon, V. Schnitzler, O. Gauthier, F. Boukhechba, E. Verron, D. Massiot, P. Janvier, J.-M. Bouler, Bruno Bujoli Design and properties of novel gallium-doped injectable apatitic cements' Acta Biomater. (2015) 24:322-32

J. Zhang, W. Liu, V. Schnitzler, F. Tancret, J.-M. Bouler Calcium phosphate cements for bone substitution: chemistry, handling and mechanical properties' Acta Biomater. (2014) 10(3): 1035-49

E. Verron, M-L Pissonnier, V. Schnitzler, B.H. Fellah, J. Lesoeur, P. Pilet, H. Pascal-Moussellard, O. Gauthier, J.-M. Bouler Vertebroplasty using bisphosphonate-loaded calcium phosphate cement in a standardized vertebral body bone defect on an osteoporotic sheep model' Acta Biomater. (2014) 10(11):4887-95.

V. Schnitzler, F. Fayon, C. Despas, I. Khairoun, C. Mellier, T. Rouillon, D. Massiot, A. Walcarius, P. Janvier, O. Gauthier, G. Montavon, J.-M. Bouler, B. Bujoli Investigation of alendronate-doped Apatitic Cements as a Potential Technology for the Prevention of Osteoporotic Hip Fractures. Critical Influence of the Drug Introduction Mode on the In Vitro Cement Properties.' Acta Biomater (2011) 7(2):759-70

E. Verron, J.-M. Bouler, J.-C. Scimeca Gallium as a potential candidate for treatment of osteoporosis ?' Drug Discov. Today.(2012), 17(19/20): 1127-32